This will be an important year for Axsome Therapeutics, as they transform from a pure drug development company, to a drug development plus commercialization company. Below are some projected timelines that the company is planning on achieving for the first half of 2021.
- AXS-05 for MDD, new drug application to be accepted by the FDA mid April.
- AXS-07 for acute migraine, new drug application to be filed in April.
- AXS-07 new drug application to be accepted by the FDA in June.
- AXS-12 starts Phase 3 for narcolepsy in the second quarter.
The weekly chart above illustrates that axsm has been trading in a range for the past ten months. As it currently stands today, the stock is at the lower bounds of the range making it a lower risk entry, for those looking to invest in the company.
No comments:
Post a Comment